ONWARD Announces First-in-Human Use of ARC-IM™ Lead to Restore Movement and Function after Spinal Cord Injury
New lead is purpose-designed to optimize the delivery of ONWARD ARC Therapy™
EINDHOVEN, the Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced the successful first-in-human use of its investigational ARC-IM Lead.
The ARC-IM Lead delivers targeted electrical pulses to the spinal cord and is a key component of the ONWARD ARC-IM system, an innovative platform engineered to deliver ARC Therapy to address multiple indications. The ARC-IM Lead is designed to be used with the ARC-IM neurostimulator (IPG) and is purpose-built for placement along the spinal cord to stimulate the dorsal roots, with specific parameters designed for each anatomical location. ONWARD is developing a portfolio of ARC-IM Leads in a range of sizes, shapes, and electrode arrays for the many indications the Company is developing or exploring, such as improved blood pressure management, mobility, upper extremity function, and bladder control.
The ARC-IM Lead was implanted today by Jocelyne Bloch, MD, neurosurgeon at Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland, to benefit a patient with poor blood pressure regulation following SCI.
“The shape and electrode placement of the ARC-IM Lead are unique, providing characteristics I have long wanted for my patients with spinal cord injury, while exhibiting the same feel as the leads I have implanted for many years,” said Dr. Bloch.
During today’s surgery, the ARC-IM Lead was placed in the “Hemodynamic Hotspot” along the thoracic spinal cord, an area in which targeted electrical stimulation may restore better blood pressure regulation after an SCI. This specific location and accompanying mechanism of action were first discovered by the Company’s research partners at the Swiss Federal Institute of Technology Lausanne (EPFL) and University of Calgary and published in Nature in January 2021.
In December 2022, ONWARD announced positive interim results from the first ten people treated with targeted ARC-IM Therapy to improve blood pressure regulation following SCI. All participants reported improved quality of life. ONWARD received an FDA Breakthrough Device Designation in 2021 for this indication.
“The purpose-designed ARC-IM Lead will unlock our ability to optimally deliver ARC Therapy to address many of the challenges faced by people with spinal cord injury,” said Dave Marver, CEO of ONWARD. “We look forward to using the lead to pursue restoration of mobility and other indications in the future.”
All ONWARD devices and therapies referenced here, including but not limited to ARC-IM, ARC-EX, and ARC Therapy, are investigational and not available for commercial use.
About ONWARD® Medical
ONWARD is a medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injuries. The Company’s work builds on more than a decade of basic science and preclinical research conducted at the world’s leading neuroscience laboratories. ONWARD ARC Therapy™, which can be delivered by implantable (ARC-IM™) or external (ARC-EX®) systems, is designed to deliver targeted, programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life.
ONWARD has received eight Breakthrough Device Designations from the U.S. FDA. ARC-EX is an external, non-invasive platform consisting of a stimulator and wireless programmer. Positive top-line data were reported in 2022 from the Company’s first pivotal study, called Up-LIFT, evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The Company is now preparing marketing approval submissions for the US and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The Company completed the first-in-human use of the ARC-IM neurostimulator and reported positive interim clinical outcomes for ARC-IM Therapy for improved blood pressure regulation following SCI in 2022.
ONWARD is headquartered in Eindhoven, the Netherlands. It maintains a Science and Engineering Center in Lausanne, Switzerland, and has a growing U.S. presence in Boston, Massachusetts. The Company has an academic partnership with .NeuroRestore, a collaboration between EPFL, the Swiss Federal Institute of Technology in Lausanne, and Lausanne University Hospital (CHUV). For additional information about the Company, please visit ONWD.com. To access our 2023 Financial Calendar, please visit IR.ONWD.com.
For Company Enquiries:
For Media Enquiries:
Aditi Roy, VP Communications
For Investor Enquiries:
Lara Smith Weber, CFO
Certain statements, beliefs, and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve several risks, uncertainties, and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition, and technology, can cause actual events, performance, or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions, or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Seafood “Canton Fair” Brings New Business Opportunities to Seize the China Seafood Market2.6.2023 04:17:37 CEST | Press release
GUANGZHOU, China, June 01, 2023 (GLOBE NEWSWIRE) -- The Global Seafood Trade Fair will be held in Guangzhou, China, from June 28th to 30th, 2023. It is organized by the China Aquatic Products Processing and Marketing Alliance and the China Aquatic Production Chamber of Commerce and managed by Wuhan Shihedao Network Technology Co., Ltd. With over 800 exhibitors and a 40,000 ㎡exhibition area, the Global Seafood Trade Fair will showcase a wide range of aquatic products, frozen goods, processed seafood, and related equipment, covering the entire industry chain of production, processing, and seafood trade. In addition, the exhibition will hold more than 20 onsite events, providing exhibitors with multiple opportunities for business exchange and collaboration, focusing on matching supply and demand, and promoting an efficient one-stop procurement and communication platform. This exhibition will provide you with a unique opportunity to explore the global catering market as well as go deeper i
Webull Australia avails Cboe US Options2.6.2023 01:00:00 CEST | Press release
SYDNEY, Australia, June 02, 2023 (GLOBE NEWSWIRE) -- Webull Securities (Australia) Pty. Ltd. ("Webull AU"), an Australian brokerage firm licensed by the Australian Securities Investment Commission that operates on the popular Webull trading platform, has announced the launch of a suite of Cboe Global Markets (Cboe) US index options on 23 April 2023. This new offering allows Australian retail investors access to cash-settled index options trading through Cboe’s popular US options suite, including the S&P 500 Index (SPX) options, Cboe Volatility Index (VIX) options and Mini-S&P 500 Index (XSP) options. The addition is an extension to Webull AU's existing US options offering and furthers Cboe’s and Webull’s commitment to offering new and innovative products and education resources to retail investors across the globe. The S&P 500 Index is the global benchmark of large-cap US equities and the VIX Index is the world's premier gauge of expected US equity market volatility. The introduction o
Westport Announces Effective Date of Share Consolidation1.6.2023 23:00:00 CEST | Press release
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Westport Fuel Systems Inc. ("Westport" or the "Company") (TSX:WPRT / Nasdaq: WPRT) a global leader in low-emissions alternative fuel transportation technologies is pleased to announce, further to its April 26, 2023 press release, the completion of the Company's proposed consolidation of its common shares ("Common Shares") on the basis of (1) new post-consolidation Common Share for every ten (10) existing pre-consolidation Common Shares (the "Consolidation"). As of the date hereof, and following the Consolidation, there are 17,174,972 Common Shares issued and outstanding. Immediately prior to the Consolidation, the Company had 171,751,409 Common Shares issued and outstanding. No fractional Common Shares will be issued pursuant to the Consolidation and any fractional shares that would otherwise be issued will be rounded down to the nearest whole Common Share. A letter of transmittal with respect to the Consolidation is being
Constellation Brands to Report First Quarter Fiscal 2024 Financial Results; Host Conference Call June 30, 20231.6.2023 22:30:41 CEST | Press release
VICTOR, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today it will report financial results for its first quarter ended May 31, 2023, on Friday, June 30, 2023, before the open of the U.S. markets. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer, Bill Newlands, and Executive Vice President and Chief Financial Officer, Garth Hankinson, at 10:30 a.m. EDT, June 30, 2023. The conference call can be accessed by dialing +1-877-407-9121 and entering conference identification number 13739041, beginning at 10:20 a.m. EDT. A live, listen-only webcast of the conference call will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the call begins, financial information discussed on the conference call, and reconciliations of reported GAAP financial measures with comparable and other non-GA
Amlan International Names Beijing Zhongnong Pasture Biotechnology Co., Ltd. as Master Distributor in China1.6.2023 22:03:55 CEST | Press release
CHICAGO, June 01, 2023 (GLOBE NEWSWIRE) -- Amlan® International, the animal health business of Oil-Dri® Corporation of America and a global leader in mineral-based feed additives that optimize the intestinal health of poultry and livestock, is proud to announce its strategic restructuring plans for the China business. To streamline distribution and increase efficiency, Amlan has chosen Beijing Zhongnong Pasture Biotechnology Co., Ltd. as its master distributor in China. The strategic decision recognizes the significance of the Chinese market and Amlan’s successful longstanding partnership with Zhongnong. In 2021, China had the world’s largest swine meat production, 53 million MT, producing 44% of global production. Additionally, China was the world’s second largest broiler meat producer, producing 14.7 million MT, and the world’s third largest milk producer, producing 36.8 million MT in the same year. With nearly 20 years of experience serving the Chinese feed and farming industry, Zho